The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ENOB | -82.07% | -96.9% | -50.08% | -98% |
| S&P | +16.23% | +94.45% | +14.22% | +148% |
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
The company scores an exclusive license for new potential coronavirus treatment technology.
The biotech's experimental treatment for HIV could be a game changer.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | -4.8% |
| Market Cap | $51.25M | -80.6% |
| Market Cap / Employee | $1.77M | 0.0% |
| Employees | 29 | 16.0% |
| Net Income | -$126.73M | -439.1% |
| EBITDA | -$4.08M | 24.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.09M | -58.0% |
| Accounts Receivable | $1.07M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.42M | -49.6% |
| Short Term Debt | $10.02M | 240.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -207.76% | -120.9% |
| Return On Invested Capital | -63.38% | -11.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.81M | 25.7% |
| Operating Free Cash Flow | -$1.81M | 25.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.79 | 1.65 | 1.00 | -2.40 | -222.16% |
| Price to Tangible Book Value | -27.36 | -65.47 | -33.93 | -19.33 | -69.62% |
| Enterprise Value to EBITDA | -14.22 | -31.29 | -22.87 | -14.23 | -72.46% |
| Return on Equity | -181.2% | -213.2% | -67.1% | -321.8% | 198.53% |
| Total Debt | $3.82M | $6.37M | $7.03M | $10.45M | 175.82% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
